Dengue Vaccine Market 2025

Dengue Vaccine Market Definition

A dengue vaccine is a biological preparation designed to protect individuals against dengue fever, a viral infection caused by the dengue virus (DENV). This virus is transmitted primarily through the bite of infected Aedes mosquitoes, especially Aedes aegypti. Dengue fever causes a range of symptoms, from mild flu-like illness to severe complications such as dengue hemorrhagic fever and dengue shock syndrome, which can be life-threatening. The dengue vaccine market consists of sales by entities (organizations, sole traders and partnerships) of dengue vaccine that focuses on providing solutions to mitigate the severe health risks associated with the disease, which can range from flu-like symptoms to life-threatening complications like dengue hemorrhagic fever and dengue shock syndrome.

Dengue Vaccine Market Size

The global dengue vaccine market reached a value of nearly $408.19 million in 2024, having grown at a compound annual growth rate (CAGR) of 174.86% since 2019. The market is expected to grow from $408.19 million in 2024 to $987.42 million in 2029 at a rate of 19.32%. The market is then expected to grow at a CAGR of 16.77% from 2029 and reach $2,143.49 million in 2034. Growth in the historic period resulted from the rising dengue incidence, expansion of vaccination programs, public awareness campaigns and increasing healthcare infrastructure. Factors that negatively affected growth in the historic period was limited vaccine availability. Going forward, the increasing healthcare expenditure, strong economic growth in emerging markets, favorable government initiatives and increasing number of population will drive the growth. Factor that could hinder the growth of the dengue vaccine market in the future include economic constraints.

Dengue Vaccine Market Drivers

The key drivers of the dengue vaccine market include: Increasing Healthcare Expenditure The increasing healthcare expenditure is expected to propel the growth of the dengue vaccine market during the forecast period. Increased healthcare budgets in dengue-endemic regions drive vaccine development, distribution and public health initiatives. Greater funding enhances public awareness, accelerates R&D and improves healthcare infrastructure, making vaccines more accessible. This boosts market growth, supports immunization programs and ensures broader vaccine availability, benefiting at-risk populations. For instance, according to the economic forecast from the Office for Budget Responsibility (OBR) and Treasury, planned health spending in the UK is expected to rise to £192 billion ($244.43 billion) in 2024/2025 from £182 billion ($231.70 billion) in 2022/2023. Additionally, in July 2024, the Government of India allocated approximately INR 909.58 billion ($10.96 billion) for the healthcare sector in the FY2024-25 budget. Therefore, the increasing healthcare expenditure will drive the growth of the dengue vaccine market.

Dengue Vaccine Market Restraints

The key restraints on the dengue vaccine market include: Economic Constraints The economic constraints are expected to hinder the growth of the dengue vaccine market during the forecast period. Developing a vaccine involves significant financial investment due to the costs of clinical trials, regulatory approval and large-scale manufacturing. Many countries, especially those with low to middle incomes, may face challenges in securing the necessary funding, which could hinder market expansion in these regions. During periods of economic instability or downturns, governments may reduce healthcare spending, including on vaccines, further limiting the resources available for large-scale vaccination efforts. For example, in April 2024, according to UN Trade and Development (UNCTAD), a Switzerland-based specialized agency of the United Nations, global economic growth to decelerate to 2.6% in 2024, marginally surpassing the 2.5% threshold typically linked to economic recessions. Therefore, the increasing number of populations will drive the growth of the dengue vaccine market. Therefore, the economic constraints will restrain the growth of the dengue vaccine market.

Dengue Vaccine Market Trends

Major trends shaping the dengue vaccine market include: Advancements In Diagnostic Kits For Early Detection Of Dengue Infections Leading companies in the dengue vaccine market are prioritizing the development of innovative diagnostic kits to facilitate early detection, improve diagnostic accuracy and enable timely treatment of dengue infections. These advanced tools are designed to enhance the efficiency and accessibility of disease detection by leveraging modern techniques and technologies, addressing traditional diagnostic challenges such as slow processing times, limited sensitivity and complicated procedures. For example, in August 2024, J Mitra & Company, an India-based biotechnology firm specializing in the manufacturing of in-vitro diagnostic (IVD) kits and reagents launched the Dengue NS1 Antigen self-test kit. This self-testing kit enables individuals to conveniently perform dengue tests anywhere, offering greater accessibility to diagnostic solutions. The kit delivers results within 20 minutes through a rapid visual test that ensures straightforward interpretation. Designed to detect all four serotypes of the dengue virus, it provides comprehensive and accurate diagnostics. Its core functionality lies in identifying the Dengue NS1 Antigen from the first day of fever onset, facilitating prompt medical intervention. Investment In Novel Dengue Treatment Solutions To Address Rising Global Incidence Major companies operating in the dengue vaccine market are focusing on strategic investments to expand their product portfolios, enhance vaccine efficacy and improve global access. Strategic investments drive the growth of the dengue vaccine market by boosting funding for research and development, allowing manufacturers to develop more efficient and advanced vaccines. For instance, in October 2023, Codagenix Inc., a US-based clinical-stage biotechnology company focused on developing vaccines received an award of $5.88 million from U.S. Department of Defense (DoD) to further develop its dengue vaccine candidate, CodaVax-DENV. The funding will support the initiation of a first-in-human Phase 1 trial, which will evaluate the vaccine's safety and immunogenicity. This initiative aligns with a broader strategy to combat dengue fever, a significant health threat, particularly for military personnel deployed in endemic regions.

Opportunities And Recommendations In The Dengue Vaccine Market

Opportunities – The top opportunities in the dengue vaccine market segmented by type will arise in the live attenuated vaccine segment, which will gain $547.04 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by route of administration will arise in the parenteral segment, which will gain $538.24 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by end user will arise in the hospitals segment, which will gain $353.32 million of global annual sales by 2029. The dengue vaccine market size will gain the most in Brazil at $123.96 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the dengue vaccine companies to focus on developing innovative diagnostic kits for dengue, focus on strategic investments for vaccine development, focus on nucleic acid-based vaccines for dengue, focus on oral vaccines for dengue prevention, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for vaccine development, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, focus on government institutes for vaccine development and focus on targeting growing populations for vaccine strategies.